A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Status:
Recruiting
Trial end date:
2025-11-03
Target enrollment:
Participant gender:
Summary
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe
and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The
study will last about 12 months and may include up to 7 visits.